Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
08/2003
08/13/2003EP1333833A2 Novel compounds
08/13/2003EP1333822A2 Treatment of diseases with adamantane derivatives
08/13/2003EP1333809A2 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
08/13/2003EP1220845B1 Aryl-sulfonamide substituted benzimidazol derivatives and use of said as tryptase inhibitors
08/13/2003EP1073658B1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
08/13/2003EP0891328B1 Peptidyl compounds having mmp and tnf inhibitory activity
08/13/2003EP0879233B1 Chinoline and benzimidazole derivatives as bradykinin agonists
08/13/2003CN1436235A Anti-angiogenic polypeptides
08/13/2003CN1436188A 1,3,8-triaza-spiroÒÇö4,5ÒÇòdecan-4-one derivs. as neurokinin receptor antagonists
08/13/2003CN1436084A Remedies for allergic diseases and process for producing same
08/13/2003CN1436048A Infant formulas contg. long-chain polyunsaturated fatty acids and uses thereof
08/12/2003US6605725 Treating a central or peripheral nervous system disorder or condition through modulation of a voltage-dependent potassium channel
08/12/2003US6605722 Tyrosine derivatives with anti-leukotrienen activity
08/12/2003US6605702 Protein for use in the treatment of inflammatory defects and asthma
08/12/2003US6605640 Treating a retinal or choroidal vascular or hereditary disease by topically administering an acetylcholine esterase inhibitor, e.g., Phospholine Iodide; age related macular degeneration disease; diabetic retinopathy
08/12/2003US6605634 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
08/12/2003US6605609 N-(((5S)-3-(4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophen yl) -2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide antimicrobial used in combination therapy
08/12/2003US6605603 Uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid
08/12/2003US6605592 Protein HOFNF53
08/12/2003US6605295 Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin
08/12/2003CA2212836C Substituted isoxazoles for the treatment of inflammation
08/07/2003WO2003065046A2 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
08/07/2003WO2003064685A2 Genetic polymorphisms in the preprotachykinin gene
08/07/2003WO2003064626A2 Double-stranded oligonucleotides
08/07/2003WO2003064625A2 Oligonucleotide compositions with enhanced efficiency
08/07/2003WO2003064622A2 Aggrecanase molecules
08/07/2003WO2003064443A2 New corticosteroids
08/07/2003WO2003064387A2 Substituted indoles as alpha-1 agonists
08/07/2003WO2003064383A2 Phosphorus-containing compounds & uses thereof
08/07/2003WO2003064369A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003WO2003063879A1 Remedies for glaucoma comprising bunazosin and prostaglandins
08/07/2003WO2003063862A1 Cotherapy with an oxazolidinone and a vitamin b
08/07/2003WO2003063859A1 Suppression of cartilage degradation via the estrogen receptor
08/07/2003WO2003063848A1 Lutein/zeaxanthin for glare protection
08/07/2003WO2003063845A1 Alpha 2 delta ligands to treat tinnitus
08/07/2003WO2003063826A2 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same
08/07/2003WO2003063800A2 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/07/2003WO2003063794A2 2,4-pyrimidinediamine compounds and their uses
08/07/2003WO2002055541A3 Peptides having inhibiting activity on the production of nitric oxide
08/07/2003WO2002004015A9 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
08/07/2003WO2002002593A3 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
08/07/2003WO2002000172A3 Methods for using tetanus toxin for benificial purposes in animals (mammals)
08/07/2003US20030149277 Triarylimidazole derivatives as cytokine inhibitors
08/07/2003US20030149266 Administering to a patient (a warm blooded animal, such as man) an effective amount of a pyrimidine derivative for treating cancer, cell proliferation, and inhibition of focal adhesion kinase effect
08/07/2003US20030149237 G-protein coupled receptor for treatment and prevention of eating, cancer, autoimmune, vision and nervous sytem disorders; antiinflammatory agents
08/07/2003US20030149110 For use as as neuro-protective agents for therapy of conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine
08/07/2003US20030149107 For therapy of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis
08/07/2003US20030149091 For therapy of inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder
08/07/2003US20030149081 For therapy and prophylaxis of asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, inflammatory bowel disease, atherosclerosis
08/07/2003US20030149068 Use of chrysanthone A for the preparation of a medicament with antiangiogenic activity
08/07/2003US20030149067 Crystallisation of the desired crystalline form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals
08/07/2003US20030149058 Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
08/07/2003US20030149047 Novel compounds
08/07/2003US20030149046 Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof
08/07/2003US20030149039 For therapy of disease responsive to antagonist modulation of the Neurokinin-1 (NK-1) receptor in a patient
08/07/2003US20030149037 For therapy and prophylaxis of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, etc.
08/07/2003US20030149012 Vision through photodynamic therapy of the eye
08/07/2003US20030149003 Functionalized stilbene derivatives as improved vascular targeting agents
08/07/2003US20030148964 Single dose azithromycin
08/07/2003US20030148945 Antimicrobial and anti-inflammatory peptides
08/07/2003US20030148513 Preparing culture of pluripotent brain tissue for nervous tissue regeneration, tissue engineering and treating nervous system disorders
08/07/2003US20030147937 Di-myo-inositol phosphate, cyclic 2,3 diphosphoglycerate, 1,1-di- glycerol phosphate, mannosylglycerate, mannosyl glyceramide and/or di-mannosyl-di-inositol phosphate; protecting organisms, organs, tissues, cells from oxidation
08/07/2003US20030147922 Vaccine against streptococcus pneumoniae capsular polysaccharides
08/07/2003US20030147903 ABC transport polynucleotides, polypeptides and antibodies
08/07/2003US20030147876 Combination of a growth factor and a protease enzyme
08/07/2003CA2475003A1 Double-stranded oligonucleotides
08/07/2003CA2474910A1 Oligonucleotide compositions with enhanced efficiency
08/07/2003CA2474908A1 Aggrecanase molecules
08/07/2003CA2474349A1 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same
08/07/2003CA2474277A1 2,4-pyrimidinediamine compounds and their uses
08/07/2003CA2474000A1 Alpha 2 delta ligands to treat tinnitus
08/07/2003CA2473803A1 Substituted indoles as alpha-1 agonists
08/07/2003CA2473457A1 Cotherapy with an oxazolidinone and a vitamin b
08/07/2003CA2473249A1 New corticosteroids
08/07/2003CA2473162A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003CA2473128A1 Genetic polymorphisms in the preprotachykinin gene
08/07/2003CA2443023A1 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/06/2003EP1332372A2 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
08/06/2003EP1332149A1 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
08/06/2003EP1332147A1 Thieno[2,3-c isoquinolines for use as inhibitors of parp
08/06/2003EP1332146A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332144A1 Indole derivatives as pde5-inhibitors
08/06/2003EP1332136A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332134A2 Inhibitors of prenyl-protein transferase
08/06/2003EP1332131A2 Acid derivatives useful as serine protease inhibitors
08/06/2003EP1331945A2 Otic microbial combinations for treatment of animals with ruptured tympanic membrane
08/06/2003EP1331940A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
08/06/2003EP1331935A2 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
08/06/2003EP1331931A2 Treatment of tinnitus
08/06/2003EP1331902A2 Improved ophthalmic and contact lens solutions containing forms of vitamin b
08/06/2003EP1165544B1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
08/06/2003EP1117648B1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors
08/06/2003EP0983064B1 PYRROLES AS sPLA2 INHIBITORS
08/06/2003EP0804419B1 Quinoline derivatives as tachykinin nk 3 receptor antagonists
08/06/2003CN1434823A 3-thiazol-4-yl-pyprolidine derivatives as AMP-specific phosphodiesterase inhibitors
08/06/2003CN1434820A Cyclic AMP-specific phosphodiesterase inhibitors
08/06/2003CN1434813A Pyrrolidine derivatives cyclic AMP-specific phosphodiesterase inhibitors
08/06/2003CN1434812A Thizaolyl amide derivatives
08/06/2003CN1434799A Cyclic amp-specific phosphodiesterase inhibitors
08/06/2003CN1434798A Pyrrolidines which inhibit CAMP-specific PDE
1 ... 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 ... 531